NeoImmuneTech to Present at the 2020 Biotech Showcase

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, today announced that it will present a company overview at the Biotech Showcase 2020 conference, taking place at the Hilton Union Square in San Francisco, CA.

NeoImmuneTech's Chief Business Officer, Samuel Zhang, Ph.D., MBA, will review NeoImmuneTech's recent progress and future directions, including an update on the company's lead drug candidate, Hyleukin-7tm. NeoImmuneTech is currently conducting several clinical trials of Hyleukin-7 in different types of cancer and multiple pre-IND and non-clinical studies in both solid tumors and hematologic malignancies.

Presentation details:
Date: Tuesday, January 14
Time: 3:00pm PT
Track: Franciscan B (Ballroom Level)
Location: Hilton Hotel, Downtown San Francisco, CA

About Hyleukin-7tm

Hyleukin-7tm, the only clinical-stage long-acting human IL-7, is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for T-cell development and for sustaining immune response to chronic antigens (as in cancer). Hyleukin-7's favorable PK/PD and safety profiles make it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. Hyleukin-7 is being studied in multiple clinical trials in solid tumors, and is being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech

NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the immuno-oncology frontier with Hyleukin-7 and beyond. NIT is partnering with industry and academic leaders to investigate Hyleukin-7 in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.